Join
Live feed
·
PRReleasevia Quantisnow
Denali Therapeutics Inc. logo

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

ByQuantisnow·Wall Street's wire, on your screen.
DNLI· Denali Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNLI (Denali Therapeutics Inc.) and more on Quantisnow.